• Je něco špatně v tomto záznamu ?

The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study

J. Burisch, D. Bergemalm, J. Halfvarson, V. Domislovic, Z. Krznaric, A. Goldis, JF. Dahlerup, P. Oksanen, P. Collin, L. de Castro, V. Hernandez, S. Turcan, E. Belousova, R. D'Incà, A. Sartini, D. Valpiani, M. Giannotta, R. Misra, N. Arebi, D....

. 2020 ; 8 (8) : 949-960. [pub] 20200726

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026549

BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice. AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease. METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists. RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)). CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.

1st Department of Medicine Semmelweis University Budapest Hungary

Clinic of Gastroenterology University of Medicine 'Victor Babes' Timisoara Romania

Department of Biomedicine Porto University Porto Portugal

Department of Gastroenterology 53176Herlev Hospital University of Copenhagen Denmark

Department of Gastroenterology and Alimentary Tract Surgery Tampere University Hospital Tampere Finland

Department of Gastroenterology and Liver Diseases 26732Ben Gurion University of the Negev Beer Sheva Israel

Department of Gastroenterology Azienda USL Toscana Centro Florence Italy

Department of Gastroenterology Centro Hospitalar de São João EPE Porto Portugal

Department of Gastroenterology Complexo Hospitalario Universitario de Vigo Vigo Spain

Department of Gastroenterology Hepatology and Nutrition 162072University Hospital Centre Zagreb Zagreb Croatia

Department of Gastroenterology Lithuanian University of Health Sciences Kaunas Lithuania

Department of Gastroenterology Moscow Regional Research Clinical Institute Moscow Russian Federation

Department of Gastroenterology North Zealand University Hospital Frederikssund Denmark

Department of Gastroenterology Örebro University Örebro Sweden

Department of Gastroenterology State University of Medicine and Pharmacy of the Republic of Moldova Chisinau Republic of Moldova

Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark

Department of Internal Medicine 26732Ben Gurion University of the Negev Beer Sheva Israel

Department of Internal Medicine Csolnoky Ferenc Regional Hospital Veszprem Hungary

Department of Medicine Herning Central Hospital Herning Denmark

Department of Surgical Oncological and Gastroenterological Sciences University of Padua Padova Italy

Digestive Diseases Research Group Galicia Sur Health Research Institute Vigo Spain

Division of Gastroenterology 223089Mater Dei Hospital Msida Malta

Division of Gastroenterology McGill University Health Center Montreal Canada

Division of Gastroenterology University Hospital and University of Ioannina Greece

Division of Gastroenterology University of Tarty Tartu Estonia

Faculty of Medicine and Health Technology Tampere University Tampere Finland

Gastroenterology Department Odense University Hospital Odense Denmark

Gastroenterology Department Slagelse Hospital Slagelse Denmark

Gastroenterology Unit 26993Amiens University Hospital Amiens France

Hull University Teaching Hospitals NHS Trust Hull UK

Hull York Medical School Hull UK

IBD Clinical and Research Centre ISCARE Prague Czech Republic

IBD Department Imperial College London London UK

Institute for Digestive Research Lithuanian University of Health Sciences Kaunas Lithuania

Institute for Translational Research in Inflammation Lille University Lille France

Institute of Molecular Medicine University of Southern Denmark Odense Denmark

Institute of Pharmacology Charles University Prague Prague Czech Republic

IRS Center Soenderjylland University Hospital of Southern Denmark Aabenraa Denmark

Medical Department The National Hospital of the Faroe Islands Torshavn Faroe Islands

Private practice Nicosia Cyprus

Public Health Epidemiology and Economic Health Lille University and Hospital Lille France

School of Medicine University of Zagreb Zagreb Croatia

UO Gastroenterologia ed Endoscopia digestiva Hospital Morgagni Pierantoni Forlì Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026549
003      
CZ-PrNML
005      
20211026132819.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2050640620945949 $2 doi
035    __
$a (PubMed)32715989
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Burisch, Johan $u Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark
245    14
$a The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study / $c J. Burisch, D. Bergemalm, J. Halfvarson, V. Domislovic, Z. Krznaric, A. Goldis, JF. Dahlerup, P. Oksanen, P. Collin, L. de Castro, V. Hernandez, S. Turcan, E. Belousova, R. D'Incà, A. Sartini, D. Valpiani, M. Giannotta, R. Misra, N. Arebi, D. Duricova, M. Bortlik, K. Gatt, P. Ellul, N. Pedersen, J. Kjeldsen, KW. Andersen, V. Andersen, KH. Katsanos, DK. Christodoulou, S. Sebastian, L. Barros, F. Magro, JM. Midjord, KR. Nielsen, R. Salupere, HA. Kievit, G. Kiudelis, J. Kupčinskas, M. Fumery, C. Gower-Rousseau, IP. Kaimakliotis, D. Schwartz, S. Odes, L. Lakatos, PL. Lakatos, E. Langholz, P. Munkholm, Epi-IBD group
520    9_
$a BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice. AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease. METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists. RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)). CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.
650    _2
$a dospělí $7 D000328
650    _2
$a antiflogistika nesteroidní $x terapeutické užití $7 D000894
650    _2
$a biologické faktory $x terapeutické užití $7 D001685
650    _2
$a kolektomie $x statistika a číselné údaje $7 D003082
650    _2
$a Crohnova nemoc $x diagnóza $x imunologie $x terapie $7 D003424
650    _2
$a progrese nemoci $7 D018450
650    _2
$a kombinovaná farmakoterapie $x metody $x statistika a číselné údaje $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x terapeutické užití $7 D007155
650    _2
$a udržovací chemoterapie $x metody $x statistika a číselné údaje $7 D060046
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mesalamin $x terapeutické užití $7 D019804
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bergemalm, Daniel $u Department of Gastroenterology, Örebro University, Örebro, Sweden
700    1_
$a Halfvarson, Jonas $u Department of Gastroenterology, Örebro University, Örebro, Sweden
700    1_
$a Domislovic, Viktor $u Department of Gastroenterology, Hepatology and Nutrition, 162072University Hospital Centre Zagreb, Zagreb, Croatia
700    1_
$a Krznaric, Zeljko $u Department of Gastroenterology, Hepatology and Nutrition, 162072University Hospital Centre Zagreb, Zagreb, Croatia $u School of Medicine, University of Zagreb, Zagreb, Croatia
700    1_
$a Goldis, Adrian $u Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania
700    1_
$a Dahlerup, Jens F $u Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Oksanen, Pia $u Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland $u Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
700    1_
$a Collin, Pekka $u Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
700    1_
$a de Castro, Luisa $u Digestive Diseases Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain $u Department of Gastroenterology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
700    1_
$a Hernandez, Vicent $u Digestive Diseases Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain $u Department of Gastroenterology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
700    1_
$a Turcan, Svetlana $u Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova
700    1_
$a Belousova, Elena $u Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation
700    1_
$a D'Incà, Renata $u Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padova, Italy
700    1_
$a Sartini, Alessandro $u UO Gastroenterologia ed Endoscopia digestiva, Hospital Morgagni Pierantoni, Forlì, Italy
700    1_
$a Valpiani, Daniela $u UO Gastroenterologia ed Endoscopia digestiva, Hospital Morgagni Pierantoni, Forlì, Italy
700    1_
$a Giannotta, Martina $u Department of Gastroenterology, Azienda USL Toscana Centro, Florence, Italy
700    1_
$a Misra, Ravi $u IBD Department, Imperial College London, London, UK
700    1_
$a Arebi, Naila $u IBD Department, Imperial College London, London, UK
700    1_
$a Duricova, Dana $u IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic $u Institute of Pharmacology, Charles University in Prague, Prague, Czech Republic
700    1_
$a Bortlik, Martin $u IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic $u Institute of Pharmacology, Charles University in Prague, Prague, Czech Republic
700    1_
$a Gatt, Kelly $u Division of Gastroenterology, 223089Mater Dei Hospital, Msida, Malta
700    1_
$a Ellul, Pierre $u Division of Gastroenterology, 223089Mater Dei Hospital, Msida, Malta
700    1_
$a Pedersen, Natalia $u Gastroenterology Department, Slagelse Hospital, Slagelse, Denmark
700    1_
$a Kjeldsen, Jens $u Gastroenterology Department, Odense University Hospital, Odense, Denmark
700    1_
$a Andersen, Karina W $u IRS-Center Soenderjylland, University Hospital of Southern Denmark, Aabenraa, Denmark
700    1_
$a Andersen, Vibeke $u IRS-Center Soenderjylland, University Hospital of Southern Denmark, Aabenraa, Denmark $u Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
700    1_
$a Katsanos, Konstantinos H $u Division of Gastroenterology, University Hospital and University of Ioannina, Greece
700    1_
$a Christodoulou, Dimitrios K $u Division of Gastroenterology, University Hospital and University of Ioannina, Greece
700    1_
$a Sebastian, Shaji $u Hull University Teaching Hospitals NHS Trust, Hull, UK $u Hull York Medical School, Hull, UK
700    1_
$a Barros, Luisa $u Department of Gastroenterology, Centro Hospitalar de São João EPE, Porto, Portugal
700    1_
$a Magro, Fernando $u Department of Gastroenterology, Centro Hospitalar de São João EPE, Porto, Portugal $u Department of Biomedicine, Porto University, Porto, Portugal
700    1_
$a Midjord, Jóngerð Mm $u Medical Department, The National Hospital of the Faroe Islands, Torshavn, Faroe Islands
700    1_
$a Nielsen, Kári R $u Medical Department, The National Hospital of the Faroe Islands, Torshavn, Faroe Islands
700    1_
$a Salupere, Riina $u Division of Gastroenterology, University of Tarty, Tartu, Estonia
700    1_
$a Kievit, Hendrika Al $u Department of Medicine, Herning Central Hospital, Herning, Denmark
700    1_
$a Kiudelis, Gediminas $u Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania
700    1_
$a Kupčinskas, Juozas $u Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania $u Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania
700    1_
$a Fumery, Mathurin $u Gastroenterology Unit, 26993Amiens University Hospital, Amiens, France
700    1_
$a Gower-Rousseau, Corinne $u Public Health, Epidemiology and Economic Health, Lille University and Hospital, Lille, France $u Institute for Translational Research in Inflammation (Infinite), Lille University, Lille, France
700    1_
$a Kaimakliotis, Ioannis P $u Private practice, Nicosia, Cyprus
700    1_
$a Schwartz, Doron $u Department of Gastroenterology and Liver Diseases, 26732Ben-Gurion University of the Negev, Beer Sheva, Israel
700    1_
$a Odes, Selwyn $u Department of Internal Medicine, 26732Ben-Gurion University of the Negev, Beer Sheva, Israel
700    1_
$a Lakatos, Laszlo $u Department of Internal Medicine, Csolnoky Ferenc Regional Hospital, Veszprem, Hungary
700    1_
$a Lakatos, Peter L $u 1st Department of Medicine, Semmelweis University, Budapest, Hungary $u Division of Gastroenterology, McGill University Health Center, Montreal, Canada
700    1_
$a Langholz, Ebbe $u Department of Gastroenterology, 53176Herlev Hospital, University of Copenhagen, Denmark
700    1_
$a Munkholm, Pia $u Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark
710    2_
$a Epi-IBD group
773    0_
$w MED00188834 $t United European gastroenterology journal $x 2050-6414 $g Roč. 8, č. 8 (2020), s. 949-960
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32715989 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132825 $b ABA008
999    __
$a ok $b bmc $g 1715315 $s 1147056
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 8 $c 8 $d 949-960 $e 20200726 $i 2050-6414 $m United European gastroenterology journal $n United European Gastroenterol J $x MED00188834
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace